Fig. 1.

IL-33 protected against liver injury in IRI mice.

(A) C57BL/6 mice were administered mouse recombinant IL-33 daily for 5 consecutive days before hepatic ischaemia. (B) Liver injury was assessed by serum levels of ALT. (C) Representative histological H&E staining images and statistics showing necrotic areas in livers from sham mice, IRI mice treated with vehicle (PBS), or IRI mice treated with IL-33 1 day after IRI. Bar = 200 μm. (D) The accumulation of neutrophils in livers from these mice was assessed by flow cytometry. (E and F) The production of pro-inflammatory cytokines/chemokines in the serum and mRNA expression in the livers from these mice were measured. (G and H) IL-4, IL-5, and IL-13 in the serum (G) and their mRNA expression in the livers (H) of these mice were measured. Data shown are the mean ± SEM (n = 4–6 per group). Statistical significance was assessed using a one-way ANOVA. ∗p <0.05, ∗∗p <0.01, ∗∗∗p <0.001. ALT, alanine aminotransferase; IRI, ischaemia/reperfusion injury; TNF-α, tumour necrosis factor-α.